Umifenovir Not Effective in Treating Mild COVID: Glenmark

Glenmark Pharma announced that the addition of Umifenovir did not confirm any additional benefit over Favipiravir alone in moderate COVID-19 patients.

Addition of Umifenovir did not significantly benefit over Favipiravir alone in moderate COVID-19 patients, announced Glenmark Pharma.

Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, and the trial did not meet the key endpoints.

EU Signs 63m Euro Deal to Secure Supplies of COVID-19 Drug Remdesivir
European Commission has signed a contract with American pharmaceutical company Gilead to secure doses of Veklury, the brand name for Remdesivir, for the COVID-19 treatment.

‘Favipiravir therapy and supportive care remain a suitable and effective choice for treating mild to moderate COVID-19 infection.’

Glenmark on Friday announced the results of its "FAITH" combination trial with antivirals Umifenovir and Favipiravir for the treatment of moderate hospitalized Covid-19 patients.

This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receive the emergency use authorization for Favipiravir.

This second study, titled the FAITH trial evaluated the possible superiority of the

Nitric Oxide Could Slow the Progression of COVID-19
Nitric oxide treatment can be crucial in the world's battle against SARS-CoV-2, the coronavirus that causes COVID-19, reveals a new study.

combination's efficacy against Favipiravir monotherapy.

As per the results that Glenmark presented to the regulator on Friday, the study showed no superior clinical outcomes with the addition of Umifenovir. The FAITH study enrolled in 158 hospitalized patients with moderate Covid-19 in India.

Simple Blood Test Point to Patients at Higher Risk for COVID-19 Deterioration, Death
Biomarkers, a medical indicator found in the blood, is linked to higher odds of clinical deterioration and death in COVID-19 patients, reports a new study.

The study's primary endpoint (clinical outcome measured) was the time taken from randomization to clinical cure, defined as resolution of baseline clinical signs and symptoms of Covid-19 infection and at least a 2-point improvement on WHO Ordinal Scale for Clinical Improvement, within a time frame of 28 days.

The median time to clinical cure improved by only one day (7 as compared to 8) in patients who

Coronavirus Treatment: Can Antimalarial Drug Prevent COVID-19 Infection
The FDA supports the use of antimalarial drug hydroxychloroquine in clinical trials investigating its effectiveness against COVID-19.

received the two antiviral combinations, which was not statistically significant and did not justify adding two antiviral agents.

Commenting on the trial's findings, Monika Tandon, Senior Vice President, and Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., said, "Glenmark was the first company to provide patients an oral antiviral treatment for Covid-19 in India, and this combination study was yet another effort on our part to examine new treatment options to combat the health crisis.

"These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy, along with supportive care, remains a suitable and effective choice for mild to moderate Covid-19 infection."

Source-IANS